{"id":"NCT01642589","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea","officialTitle":"Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) in Subjects 11 to 55 Years of Age in South Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-01","completion":"2013-06","firstPosted":"2012-07-17","resultsPosted":"2013-12-03","lastUpdate":"2013-12-03"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed","otherNames":["Adacel®"]}],"arms":[{"label":"Menactra® Group","type":"EXPERIMENTAL"},{"label":"Tdap - Adacel® Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to assess safety and immunogenicity of a single dose of Menactra® in support of registration of the vaccine in South Korea.\n\nPrimary Objective:\n\n* To demonstrate that the seroconversion rate is higher than 60% for serogroups A, C, Y and W-135, 28 days after a single dose of Menactra®.\n\nSecondary objectives:\n\n* To demonstrate the superiority of Menactra® versus Adacel® in terms of seroconversion rate for serogroups A, C, Y, and W-135, 28 days after a single dose of vaccine\n* To describe the safety profile after 1 dose of Menactra® or Adacel® vaccine.\n* To describe the Serum Bactericidal Assay Using Baby Rabbit (SBA-BR) Complement titers before and 28 days after a single dose of Menactra® or Adacel® vaccine.","primaryOutcome":{"measure":"Percentage of Participants With Seroconversion Following Vaccination With Either Menactra® or Adacel® Vaccine","timeFrame":"28 Days post-vaccination","effectByArm":[{"arm":"Menactra® Group","deltaMin":78,"sd":null},{"arm":"Tdap - Adacel® Group","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":7,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":200},"commonTop":["Injection Site Pain","Myalgia","Headache","Malaise","Injection Site Erythema"]}}